Evaxion Biotech A/S (NASDAQ:EVAX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a report published on Friday morning, Benzinga reports. They currently have a $14.00 price objective on the stock.

Evaxion Biotech A/S Stock Performance

Evaxion Biotech A/S stock opened at $2.99 on Friday. Evaxion Biotech A/S has a fifty-two week low of $2.26 and a fifty-two week high of $13.61. The firm’s fifty day moving average price is $3.00 and its 200-day moving average price is $3.31. The stock has a market cap of $16.18 million, a P/E ratio of -0.69 and a beta of -0.27. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.14). The business had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.10 million. During the same period in the prior year, the business posted ($2.10) earnings per share. On average, equities research analysts expect that Evaxion Biotech A/S will post -0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in EVAX. Invst LLC purchased a new stake in shares of Evaxion Biotech A/S in the 2nd quarter valued at $156,000. LM Advisors LLC bought a new stake in Evaxion Biotech A/S in the fourth quarter worth $231,000. Finally, Armistice Capital LLC boosted its position in Evaxion Biotech A/S by 6.8% during the second quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock valued at $1,137,000 after buying an additional 25,000 shares during the period. 11.04% of the stock is owned by hedge funds and other institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.